HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $280

Benzinga Newsdesk www.benzinga.com Positive 74.2%

Neg 0% Neu 0% Pos 74.2%

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $195 to $280.